Terminology
- SVT includes all tachycardias involving the atria (due to either re-entrancy or automaticity). Atrial flutter, atrial tachycardia, MAT, AF, AV node re-entrant tachycardia & AV re-entrant tachycardia. Atrial flutter, atrial tachycardia & MAT described in Arrhythmias & _AF in Atrial Fibrillation.
AV node re-entrant tachycardia (AVNRT)
- 60% of SVTs
- Micro re-entrant circuit in AV node.
Management
- ABCs, O2,
- DC cardiovert if unstable, or stable and failed pharmacological options. Otherwise:
- Vagal manoeuvres
- Pharmacological options:
- Adenosine: 6mg (can repeat at 12mg) rapid bolus IV. SE: bronchospasm (so avoid in asthma). Theophylline blocks it. CI: post cardiac transplant (→cardiac arrest).
- Verapamil: 1mg IV q5 min (don’t use β-blocker concurrently) to 15mg
- β-blockers, amiodarone and flecainide may also be used
- Prophylaxis: β-blockers, sotalol, verapamil, or digoxin
AV re-entrant tachycardia (AVRT)
- 30% of SVTs
- Pre-excitation syndrome e.g. WPW syndrome, LGL syndrome & Mahaim fibre pathway.
- Conducting accessory pathways bypassing Atria-AV node-His bundle-Perkinje fibres.
Wolff-Parkinson-White Syndrome
- Bundle of Kent – accessory pathway between an atrium & ventricle, by-passing AV node
- ~1:1000 pop (50% symptomatic), M>F. Assoc with Ebstein’s/Tricuspid anomalies, HOCM.
- Conduction down accessory pathway may be anterograde, retrograde or both.
- ECG:
- Normal i.e. concealed WPW, if only retrograde conduction possible via accessory pathway [or if conduction is currently faster through AV node (low vagal tone)]
- Else: δ wave (faster antegrade accessory conduction but slower depolarisation of ventricular myocardium compared to AV node-His → early but less steep init part of QRS), PR<120ms. Slightly QRS (>110ms), discordant ST & T changes. May show pseudo-Q or -infarction patterns (neg δ wave in inf/ant leads, prom R wave in V1-3)
- Types: Type A or C – pos δ wave & R>S in V1. Type B has neg δ wave or R<S in V1-2.
- Tachyarrhythmias (HR 200-300) may be generated by:
- Re-entry circuit involving accessory pathway (AVRT) [70-80%]
- AF or atrial flutter direct conduction to ventricles via accessory pathway, bypassing AV node (WPW+AF) [~20% AF, ~7% flutter]
- When in AVRT, conduction may be:
- Orthodromic (~90%, anterograde through AVN) is narrow like AVNRT & no δ waves
- Antidromic (10%, resting ECG likely to show δ waves) usually broad. Could → VF
- When in WPW+AF or WPW + atrial flutter:
- Irregular (AF) or regular (flutter) antidromic broad complex tachycardia. Risk+ of → VT, VF. QRS complexes change in morphology. Rate may be close to 300bpm.
Lown-Ganong-Levine
- James Pathway connects atria to AV node, His or fascicles.
- Short PR (<120ms), but no δ wave and QRS normal duration.
- Some dispute over existence.
Mahaim fibre pathway
- Right sided pathway connects AV node to ventricles, fascicles to ventricles or atria to fascicles.
- Pathway only allows antegrade conduction.
- ECG may appear normal when not in AVRT as AV node conduction preferred unless high vagal tone.
- δ waves are not generally seen.
- AVRT is always antidromic and usually has LBBB morphology.
Management of AVRT
- ABCs, O2
- Narrow complex tachycardia (Orthodromic AVRT)
- As for AVNRT
- Wide complex or irregular tachycardia (Antidromic AVRT, WPW+AF, WPW+flutter)
- DC cardioversion, starting @ 100J if unstable
- If stable, still consider DC cardioversion as may be safest option OR
- Pharmacological options:
- Procainamide 50mg/min IV until reversion or ↓BP, ↑QRS>50%, or 17mg/kg max reached. Would be first line but not available in Australia
- Flecainide 2mg/kg IV over 30min. But CI if heart not structurally OK.
- Amiodarone 150mg IV over 5-10mins (can rpt over 20min) then 900mg/24h – **some concern that amiodarone could also accelerate HR or →VF
- **Ibutilide 1mg (0.01mg/kg if <60kg) IV, may rpt.
- Avoid adenosine/CCB/BB/digoxin **as may → VT or VF
- Prophylaxis: sotalol, flecainide, amiodarone
- Electrophysiological studies and radiofrequency ablation